16 States Have Passed Laws Since 2019 Targeting PBMs’ 340B Payment Cuts

Drug reimbursement
A new tally of state laws and a new white paper are the latest signs of states' growing role in policing PBM efforts to ratchet down reimbursement for 340B-purchased drugs. | Shutterstock

Sixteen states have passed laws since 2019 addressing pharmacy benefit manager (PBM) discrimination against 340B covered entities, according to a draft summary of state action on the subject circulating among community health center advocates.

Meanwhile, two longtime 340B program policy

Read More »

HRSA Makes Tweaks to 340B Program Database

HRSA yesterday announced changes to the covered entity registration and manufacturer pricing components of 340B OPAIS, the 340B program database.

The U.S. Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) posted a notice yesterday about changes to the covered entity registration and manufacturer pricing components of 340B OPAIS, the 340B program database.

Today is the first day

Read More »

Three Drug Makers Answer HRSA’s 340B Contract Pharmacy Letters Defiantly

Lilly, Novartis, and Sanofi sent HRSA defiant responses to its May 17 letters telling the companies that their 340B contract pharmacy policies were illegal.

On May 17, the federal government told six drug companies that their 340B contract pharmacy policies were illegal, and it asked them to provide updates by June 1 on their plans to comply with the law.

At least three of

Read More »

DOJ Says Lilly and Novo Nordisk’s 340B Actions Cost Providers Over $125 Million a Month and Hurt Patients

A federal court sided with a group of Texas hospitals’ efforts to block an HHS rule.

Drug manufacturers Eli Lilly and Novo Nordisk’s denials of 340B drug discounts when covered entities use contract pharmacies are causing entities to lose more than a combined total of $125 million per month in 340B program savings, federal filings in

Read More »

NEWS ANALYSIS: Top Job at HRSA Remains Unfilled as Biden Presidency Enters its Sixth Month

HRSA recently held a webinar for hospitals ahead of their annual 340B recertification period.

Today is President Biden’s 155th day in office, and he has yet to pick someone to run the U.S. Health Resources and Services Administration (HRSA), the federal agency responsible for the 340B drug pricing program.

This normally might be a

Read More »

340B Report Publisher and CEO Examines Four Burning Questions in Contract Pharmacy Standoff

In his latest column for Omnicell, 340B Report Publisher and CEO Ted Slafsky ponders four questions that need to be addressed in the contract pharmacy standoff.

In his latest column for Omnicell, 340B Report Publisher and CEO Ted Slafsky ponders four burning questions as we approach the first anniversary of drug manufacturers stopping or placing restrictions on 340B drug discounts in the contract pharmacy setting.

Read More »

Pharma’s 340B Contract Pharmacy Limits Are Costing Providers $3.2 Billion a Year, DOJ Tells Court

Covered entities' monthly 340B savings on Sanofi products dropped from $54.2 million just before the company limited discounts on drugs shipped to contract pharmacies to about $5 million within two months, federal lawyers told a judge last week.

Hospitals, health centers, and clinics are losing a projected $3.2 billion a year in 340B program savings due to six drug manufacturers’ denials of 340B pricing on drugs shipped to contract pharmacies, the federal government said in a court filing

Read More »

DOJ and AstraZeneca Far Apart on How Company’s Lawsuit Should Proceed

AbbVie and AstraZeneca filed a pair of lawsuits to block Minnesota's law barring manufacturer 340B contract pharmacy restrictions.

Drug manufacturer AstraZeneca and the federal government are miles apart on what a federal judge should do next after ruling last week that the government had no basis for stating in December that the 340B statute unambiguously requires manufacturers to

Read More »

Government Notifies Drug Companies About 340B Contract Pharmacy Advisory Opinion’s Withdrawal

Federal district courts in Maryland and Mississippi saw various legal actions related to state 340B contract pharmacy access laws in the past week.

The federal government notified drug makers Lilly, Novo Nordisk, and Sanofi in court papers on Friday about its withdrawal of its 340B contract pharmacy legal advisory opinion, in connection with AstraZeneca’s contract pharmacy lawsuit. It said the withdrawal does not

Read More »

Biden Nominates Acting HHS Inspector General for the Job Full Time

President Biden nominated career civil servant Christi Grimm to be the next HHS Inspector General.

President Biden last Friday nominated career civil servant Christi Grimm to serve as Inspector General of the U.S. Health and Human Services Department (HHS).

The HHS Office of Inspector General (OIG) has issued numerous reports on the 340B program on

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live